Clinical Trials on IGA Glomerulonephritis in New Zealand

Total 440 results

Arrowhead Pharmaceuticals

Recruiting

Study of ARO-CFB in Adult Healthy Volunteers and Patients With Complement-Mediated Kidney Disease

IgA Nephropathy

New Zealand
Ionis Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy

Primary IgA Nephropathy

Canada, Australia, New Zealand, Singapore
Eledon Pharmaceuticals

Terminated

Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

IgA Nephropathy | IgAN

Australia, Spain, Thailand, New Zealand, Croatia, Malaysia, Philippines, Poland, Sri Lanka, United Kingdom
The George Institute
Peking University First Hospital

Completed

Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study) (TESTING)

IgA Glomerulonephritis

Canada, China, Australia, Malaysia, Hong Kong, India
Arrowhead Pharmaceuticals

Recruiting

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

IgA Nephropathy | C3 Glomerulopathy

New Zealand, Australia, Korea, Republic of, Thailand, Germany, United Kingdom, Georgia
Mayo Clinic
Mallinckrodt

Completed

Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

Proteinuria | Progressive IgA Nephropathy

United States
Mayo Clinic
Columbia University; Genentech, Inc.; Stanford University; Ohio State University; Bioge... and other collaborators

Completed

Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy

IgA Nephropathy

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Efficacy and Safety of Atacicept in IgA Nephropathy

IgA Nephropathy

United States, Japan, United Kingdom
The Rogosin Institute
Weill Medical College of Cornell University

Completed

Pilot Study of Velcade® in IgA Nephropathy

Chronic Kidney Disease | IgA Nephropathy

United States
Apellis Pharmaceuticals, Inc.

Active, not recruiting

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

Lupus Nephritis | IgA Nephropathy | Membranous Nephropathy | C3 Glomerulonephritis | Dense Deposit Disease

United States
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation

IgA Nephropathy

Colombia, Taiwan, Czechia, India, Turkey, Belgium, Netherlands, Singapore, Australia, Korea, Republic of, Thailand, Argentina, Germany, Israel, Japan, Sweden, United Kingdom, Brazil, China, Hong Kong, Norway, Finland, France, Denmark, M...
The George Institute
Peking University Institute of Nephrology

Recruiting

TESTING -ON Post-Trial ObservatioNal Cohort Study (TESTING-ON)

Kidney Diseases | Glomerulonephritis | ESRD | IgA Nephropathy

Australia, China, Canada, Hong Kong, India, Malaysia
Visterra, Inc.

Completed

Safety and Efficacy Study of VIS649 for IgA Nephropathy

Immunoglobulin A Nephropathy | Glomerular Disease | IgAN

United States, Australia, Canada, Hong Kong, India, Japan, Korea, Republic of, Malaysia, Philippines, Singapore, Spain, Sri Lanka, Taiwan, Thailand, United Kingdom
Novartis Pharmaceuticals

Recruiting

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Primary IgA Nephropathy

Japan, Korea, Republic of, United States, Denmark, France, Taiwan, Belgium, Israel, Thailand, Germany, India, Czechia, Malaysia, Argentina, Singapore, China, Australia, Norway, Turkey, United Kingdom, Brazil, Hong Kong, Netherlands, C... and more
Columbia University
Novartis Pharmaceuticals

Terminated

Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease

Diabetic Nephropathy | Focal Segmental Glomerulosclerosis | IgA Nephropathy | Glomerulonephritis, Membranous | Hypertensive Nephrosclerosis | Proteinuric Kidney Disease | Glomerulopathy (Obesity-associated)

United States
HI-Bio

Active, not recruiting

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy (IGNAZ)

Immunoglobulin A (IgA) Nephropathy

United Kingdom, Germany, Spain, Serbia, Taiwan, Australia, Japan, Korea, Republic of, Belgium, United States, Bulgaria, Czechia, Georgia, Malaysia, Philippines, Ukraine
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression (IMAGINATION)

Primary IgA Nephropathy

Korea, Republic of, Australia, Spain, United Kingdom, China, France, Taiwan, United States, Italy, Greece, Czechia, Singapore, Japan, Argentina, Germany, Brazil, Poland
Calliditas Therapeutics AB

Completed

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy (Nefigard)

Primary IgA Nephropathy

United States, Australia, Taiwan, Spain, Canada, Argentina, Belarus, Belgium, Czechia, Finland, France, Germany, Greece, Italy, Korea, Republic of, Poland, Sweden, Turkey, United Kingdom
Chinook Therapeutics U.S., Inc.

Active, not recruiting

Atrasentan in Patients With IgA Nephropathy (ALIGN)

Immunoglobulin A Nephropathy | IgA Nephropathy

United States, Spain, Canada, Taiwan, Hong Kong, China, New Zealand, United Kingdom, Korea, Republic of, Australia, Germany, France, India, Japan, Czechia, Argentina, Italy, Colombia, Ireland, Brazil, Poland, Portugal
Chinook Therapeutics, Inc.

Active, not recruiting

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

IgA Nephropathy

Korea, Republic of, United States, United Kingdom
Chinook Therapeutics, Inc.

Recruiting

Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy (ASSIST)

Immunoglobulin A Nephropathy | IgA Nephropathy

Spain, Australia, United States
Chinook Therapeutics, Inc.

Recruiting

A Study of BION-1301 in Adults With IgA Nephropathy

Immunoglobulin A Nephropathy | IgA Nephropathy

United States, Canada, Australia, Argentina, Korea, Republic of
Alexion Pharmaceuticals, Inc.

Recruiting

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) (ICAN)

Immunoglobulin A Nephropathy | IgAN

Spain, United Kingdom, United States, Italy, Belgium, Germany, Colombia, Japan, China, France, Korea, Republic of, Saudi Arabia, Thailand, Australia, Canada, Brazil, Malaysia, Poland, Taiwan, Austria, Greece, Israel, Netherlands, Arge... and more
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (APPLAUSE-IgAN)

IgA Nephropathy

United States, Taiwan, Czechia, Germany, Hungary, India, Turkey, Belgium, Netherlands, Singapore, Australia, Canada, Italy, Korea, Republic of, Spain, Thailand, Denmark, Slovenia, United Kingdom, Argentina, Brazil, Israel, Japan, France, Swed... and more
Omeros Corporation

Terminated

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

IgA Nephropathy

United States, Argentina, Australia, Belgium, Bulgaria, Canada, Czechia, Germany, Greece, Hungary, India, Italy, Korea, Republic of, Lithuania, Poland, Singapore, Slovakia, Spain, Sweden, Taiwan, Thailand, Turkey, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...

Enrolling by invitation

Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy

Immunoglobulin A Nephropathy

United States
Otsuka Pharmaceutical Development & Commercialization...

Active, not recruiting

Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A Nephropathy

United States
Alexion Pharmaceuticals, Inc.

Recruiting

Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Lupus Nephritis | Immunoglobulin A Nephropathy | IgAN | LN

Australia, Spain, United Kingdom, China, Germany, Italy, Argentina, Peru, Korea, Republic of, Taiwan, Thailand, United States, Serbia, Israel, Brazil, Turkey, Mexico, Russian Federation
Travere Therapeutics, Inc.

Recruiting

A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN (SPARTACUS)

Immunoglobulin A Nephropathy

United States, Hong Kong
Travere Therapeutics, Inc.

Active, not recruiting

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT)

Immunoglobulin A Nephropathy

United States, Australia, Belgium, Croatia, Czechia, Estonia, France, Germany, Hong Kong, Italy, Korea, Republic of, Lithuania, New Zealand, Poland, Portugal, Spain, Taiwan, United Kingdom
Alexion

Recruiting

Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) (SANCTUARY)

Lupus Nephritis | Immunoglobulin A Nephropathy

United States, Australia, Canada, France, Germany, Italy, Korea, Republic of, Netherlands, Poland, Singapore, Spain, Sweden, Taiwan, United Kingdom
University of Auckland, New Zealand
Counties Manukau Health; Auckland Medical Research Foundation; Auckland District... and other collaborators

Unknown

Cyclophosphamide in Lupus Nephritis

Systemic Lupus Erythematosus

New Zealand
Société des Produits Nestlé (SPN)

Completed

An Observational Study to Characterize Human Milk From Mothers Delivering Term SGA and AGA Infants.

Small for Gestational Age (SGA) Infants | Appropriate for Gestational Age (AGA) Infants

India
Omeros Corporation

Recruiting

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

C3 Glomerulopathy | Idiopathic Immune Complex-Mediated Glomerulonephritis

Lithuania, New Zealand, Poland, Tunisia, Turkey, United Kingdom
Travere Therapeutics, Inc.

Completed

Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy) (HONUS)

Focal Segmental Glomerulosclerosis | Immunoglobulin A Nephropathy

United States, Spain, Germany
Columbia University
Alexion Pharmaceuticals

Completed

Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy

Dense Deposit Disease | Membranoproliferative Glomerulonephritis

United States
Omeros Corporation

Unknown

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

Lupus Nephritis | IgAN | C3 Glomerulopathy | MN

United States, Hong Kong
Alexion

Terminated

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Membranoproliferative Glomerulonephritis

United States, Australia, Belgium, Italy, Netherlands
Alpine Immune Sciences, Inc.

Recruiting

An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases (RUBY-3)

Lupus Nephritis | Immunoglobulin A Nephropathy | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Membranous Nephropathy

United States, Australia, Korea, Republic of
Boston Scientific Corporation

Completed

Subcutaneous Implantable Defibrillator (S-ICD) System - CE Clinical Investigation

ACC/AHA/NASPE Class 1, IIa or IIb Indications

Netherlands, Italy, United Kingdom, New Zealand
Apellis Pharmaceuticals, Inc.

Active, not recruiting

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALE)

C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...

United States, Australia, Brazil, Czechia, France, Italy, Korea, Republic of, Netherlands, Spain, Switzerland, United Kingdom
Alexion Pharmaceuticals

Completed

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease

United Kingdom, United States
The Rogosin Institute
Weill Medical College of Cornell University; New York Presbyterian Hospital

Recruiting

Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID) (RENAL AID)

Kidney Diseases | Diabetic Nephropathy | Kidney Failure, Chronic | Lupus Nephritis | Glomerulonephritis, IGA

United States
Icahn School of Medicine at Mount Sinai

Completed

Adrenocorticotropic Hormone in Membranous Nephropathy

Membranous Nephropathy

United States
Apellis Pharmaceuticals, Inc.

Active, not recruiting

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALIANT)

C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...

United States, Spain, France, Germany, United Kingdom, Netherlands, Brazil, Israel, Japan, Australia, Austria, Italy, Switzerland, Korea, Republic of, Czechia, Belgium, Argentina, Canada, Poland
NephroNet, Inc.
Mallinckrodt

Active, not recruiting

A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients (FACT)

Fibrillary Glomerulonephritis

United States
Travere Therapeutics, Inc.

Recruiting

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases (EPPIK)

Focal Segmental Glomerulosclerosis | Immunoglobulin A Nephropathy | Minimal Change Disease | Alport Syndrome | IgA Vasculitis

United States, Italy, Netherlands, Poland, Spain, United Kingdom, Germany, Sweden
Apellis Pharmaceuticals, Inc.

Active, not recruiting

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN (NOBLE)

Renal Transplant | C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative... and other conditions

United States, Australia, Austria, United Kingdom, Brazil, Argentina, France, Italy, Netherlands, Spain, Switzerland
Chinook Therapeutics U.S., Inc.

Active, not recruiting

Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY)

Diabetic Kidney Disease | Focal Segmental Glomerulosclerosis | Immunoglobulin A Nephropathy | IgA Nephropathy | Diabetic Nephropathy Type 2 | Alport Syndrome

United States, Spain, Korea, Republic of, Australia, Italy, United Kingdom
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery

Uterine Corpus Leiomyosarcoma | Stage IIA Uterine Sarcoma | Stage IIB Uterine Sarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma | Stage IA Uterine Sarcoma | Stage IB Uterine Sarcoma | Stage IC Uterine Sarcoma

United States

Clinical Trials on IGA Glomerulonephritis in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations